FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241577181> ?p ?o ?g. }

• W4241577181 endingPage "8092" @default.
• W4241577181 startingPage "8092" @default.
• W4241577181 abstract "8092 Background: Fatigue is reported by 80–100% of patients undergoing cancer chemotherapy. Patients were queried about specific fatigue symptoms. Methods: 389 cancer patients who reported fatigue on a 10 cm. Visual Analogue Scale (VAS) (1 = ‘Not at all’ and 10 = ‘A great deal.’) during chemotherapy completed the Fatigue Symptom Checklist (FSCL) 5–7 days following their first 4 cycles. The FSCL measures the severity of 30 symptoms on a 5 point scale headed “At the moment I feel:” (1 = ‘absence of [the symptom]’ and 5 = ‘a great deal.’) Three subscales of 10 items each, (drowsiness, concentration, physical symptoms) and a total score were calculated. Results: The most common cancers were breast (56%), hematologic (13%), lung (12%), gynecologic (8%) and alimentary (6%). 76% were female and 73% of women had breast cancer. The average age was 54 for females and 61 for males. 90% were Caucasian and 6% African American. Division of patients into two groups based on the VAS fatigue score at each cycle, (2–5 = ‘less fatigued,’ and 6–10 = ‘more fatigued’) showed significant differences between total and subscale scores by degree of fatigue (all Ps < 0.001). “Feeling tired over my whole body”, “Tired in my legs”, and “Want to lie down” from the drowsiness subscale were the most severe symptoms in both groups. More fatigued patients felt these symptoms “a moderate amount” (e.g. cycle means for “tired over my whole body” were 3.1, 3.4, 3.2, and 3.1), while those who were less fatigued felt them “a little” (cycle means = 1.8, 2.3, 1.9, and 1.9). Drowsiness was the next most severe symptom. Cognitive impairment and physical symptoms were less severe. There were no significant differences in scores by gender or age group, divided at the median age of 55. Patients with lung cancer reported the most severe symptoms at all four cycles, and those with cancers of the alimentary tract reported the least severe symptoms. Conclusions: Weakness and drowsiness most often characterize the fatigue experienced by patients receiving chemotherapy, suggesting that interventions to increase stamina and improve sleep quality may be beneficial. Supported, in part, by NCI PHS grant U10 CA37420 and by ACS grant RSG-01-071-PBP No significant financial relationships to disclose." @default.
• W4241577181 created "2022-05-12" @default.
• W4241577181 creator A5013273573 @default.
• W4241577181 creator A5015939030 @default.
• W4241577181 creator A5026105126 @default.
• W4241577181 creator A5052023186 @default.
• W4241577181 creator A5058678980 @default.
• W4241577181 creator A5068100232 @default.
• W4241577181 creator A5075982466 @default.
• W4241577181 creator A5083953556 @default.
• W4241577181 date "2004-07-15" @default.
• W4241577181 modified "2023-10-01" @default.
• W4241577181 title "Symptoms experienced by fatigued patients receiving chemotherapy for cancer: A URCC CCOP study" @default.
• W4241577181 doi "https://doi.org/10.1200/jco.2004.22.90140.8092" @default.
• W4241577181 hasPublicationYear "2004" @default.
• W4241577181 type Work @default.
• W4241577181 citedByCount "0" @default.
• W4241577181 crossrefType "journal-article" @default.
• W4241577181 hasAuthorship W4241577181A5013273573 @default.
• W4241577181 hasAuthorship W4241577181A5015939030 @default.
• W4241577181 hasAuthorship W4241577181A5026105126 @default.
• W4241577181 hasAuthorship W4241577181A5052023186 @default.
• W4241577181 hasAuthorship W4241577181A5058678980 @default.
• W4241577181 hasAuthorship W4241577181A5068100232 @default.
• W4241577181 hasAuthorship W4241577181A5075982466 @default.
• W4241577181 hasAuthorship W4241577181A5083953556 @default.
• W4241577181 hasConcept C121608353 @default.
• W4241577181 hasConcept C126322002 @default.
• W4241577181 hasConcept C14184104 @default.
• W4241577181 hasConcept C1862650 @default.
• W4241577181 hasConcept C2776694085 @default.
• W4241577181 hasConcept C2778141389 @default.
• W4241577181 hasConcept C530470458 @default.
• W4241577181 hasConcept C71924100 @default.
• W4241577181 hasConceptScore W4241577181C121608353 @default.
• W4241577181 hasConceptScore W4241577181C126322002 @default.
• W4241577181 hasConceptScore W4241577181C14184104 @default.
• W4241577181 hasConceptScore W4241577181C1862650 @default.
• W4241577181 hasConceptScore W4241577181C2776694085 @default.
• W4241577181 hasConceptScore W4241577181C2778141389 @default.
• W4241577181 hasConceptScore W4241577181C530470458 @default.
• W4241577181 hasConceptScore W4241577181C71924100 @default.
• W4241577181 hasIssue "14_suppl" @default.
• W4241577181 hasLocation W42415771811 @default.
• W4241577181 hasOpenAccess W4241577181 @default.
• W4241577181 hasPrimaryLocation W42415771811 @default.
• W4241577181 hasRelatedWork W2040057289 @default.
• W4241577181 hasRelatedWork W2345682820 @default.
• W4241577181 hasRelatedWork W2361086037 @default.
• W4241577181 hasRelatedWork W2371666691 @default.
• W4241577181 hasRelatedWork W2377846754 @default.
• W4241577181 hasRelatedWork W2378043051 @default.
• W4241577181 hasRelatedWork W2378355431 @default.
• W4241577181 hasRelatedWork W2947402419 @default.
• W4241577181 hasRelatedWork W2948015309 @default.
• W4241577181 hasRelatedWork W2990875063 @default.
• W4241577181 hasVolume "22" @default.
• W4241577181 isParatext "false" @default.
• W4241577181 isRetracted "false" @default.
• W4241577181 workType "article" @default.